Rencz Fanni, Brodszky Valentin, Péntek Márta, Balogh Orsolya, Remenyik Eva, Szegedi Andrea, Holló Péter, Kárpáti Sarolta, Jókai Hajnalka, Herszényi Krisztina, Herédi Emese, Szántó Sándor, Gulácsi László
Budapesti Corvinus Egyetem Egészségügyi Közgazdaságtan Tanszék Budapest Fővám tér 8. 1093 Semmelweis Egyetem, Általános Orvostudományi Kar Klinikai Orvostudományok Doktori Iskola Budapest.
Budapesti Corvinus Egyetem Egészségügyi Közgazdaságtan Tanszék Budapest Fővám tér 8. 1093.
Orv Hetil. 2014 Nov 30;155(48):1913-21. doi: 10.1556/OH.2014.30044.
Psoriasis is a frequent, chronic, systemic immune-mediated disease mainly affecting the skin and joints.
To assess health related quality of life and cost-of-illness in moderate to severe psoriasis associated with psoriatic arthritis.
A cross-sectional questionnaire survey was conducted at two academic dermatology clinics in Hungary.
Fifty-seven patients (65% males) completed the survey with a mean age of 54.3±11.6 years and mean EQ-5D score of 0.48±0.4. Mean annual total cost was €8,977 per patient, of which 71% occurred due to biological therapy and 21% were indirect costs, respectively. Permanent work disability due to psoriasis accounted for €1,775 (95% of the indirect costs). Per patient costs of subgroups not receiving systemic therapy (21%), traditional systemic therapy (32%), and biological systemic therapy (47%) amounted to the sum of €1,729, €1,799, and €16,983, respectively.
Patients on biological therapy showed significantly better health related quality of life. As for health economics, the efficacy of systemic treatments is appropriate to be assessed together in patients with moderate to severe psoriasis associated with psoriatic arthritis, since actual health gain might exceed that reported in psoriasis or psoriatic arthritis separately.
银屑病是一种常见的慢性全身性免疫介导性疾病，主要影响皮肤和关节。
评估与银屑病关节炎相关的中度至重度银屑病患者的健康相关生活质量和疾病成本。
在匈牙利的两家学术皮肤科诊所进行了一项横断面问卷调查。
57名患者（65%为男性）完成了调查，平均年龄为54.3±11.6岁，平均EQ-5D评分为0.48±0.4。每位患者的年总平均成本为8977欧元，其中71%是由于生物治疗产生的，21%是间接成本。银屑病导致的永久性工作残疾占1775欧元（占间接成本的95%）。未接受全身治疗的亚组（21%）、传统全身治疗的亚组（32%）和生物全身治疗的亚组（47%）每位患者的成本分别为1729欧元、1799欧元和16983欧元。
接受生物治疗的患者健康相关生活质量显著更好。在健康经济学方面，对于与银屑病关节炎相关的中度至重度银屑病患者，全身治疗的疗效适合一起评估，因为实际的健康获益可能超过分别在银屑病或银屑病关节炎中报告的获益。
